Related Experiment Video
Updated: Jun 22, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
Gene polymorphisms and pharmacogenetics in rheumatoid arthritis
Ignacio Rego-Pérez1, Mercedes Fernández-Moreno, Francisco J Blanco
1Osteoarticular and Aging Research Lab, Genomic Unit, Rheumatology Division, Juan Canalejo Hospital, Xubias 84 15006- A Coruña, Spain.
Current Genomics
|June 10, 2009
Summary
Rheumatoid arthritis (RA) treatments vary due to genetic differences. Pharmacogenetics offers personalized therapies by analyzing individual genetic profiles for better rheumatoid arthritis management.
Area of Science:
- Immunology
- Genetics
- Pharmacology
Background:
- Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disease with a genetic predisposition.
- Current RA therapies, including biologics and traditional drugs, show variable patient responses.
- These response variations suggest underlying differences in genetic regulatory mechanisms among RA patients.
Purpose of the Study:
- To explore the role of genetic variations in rheumatoid arthritis (RA) treatment response.
- To highlight the potential of pharmacogenetics in tailoring RA therapies.
- To investigate the functional and evolutionary significance of genetic polymorphisms in immune system regulation and drug metabolism.
Main Methods:
- Review of existing literature on rheumatoid arthritis (RA) genetics and pharmacogenetics.
- Analysis of polymorphisms in non-coding gene-regulatory regions and drug-metabolizing enzymes.
- Exploration of genetic variations influencing therapeutic efficacy and disease progression.
Main Results:
- Extensive genetic polymorphisms exist in immune system regulatory regions and drug-metabolizing enzymes.
- These genetic variations contribute to differential patient responses to RA therapies.
- Non-coding DNA variations are functionally and evolutionarily significant in RA.
Conclusions:
- Individual genetic profiles significantly impact rheumatoid arthritis (RA) treatment outcomes.
- Pharmacogenetics provides a promising avenue for personalized medicine in RA.
- Understanding genetic variations can lead to the development of novel therapeutic strategies for RA.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...